EGFR and cancer: This approach has been demonstrated in using an anti-EGFR antibody as a targeting ligand with CPP acting as an efficient facilitator of cellular uptake, resulting in specific delivery of siRNA to EGFR-positive cancer cells without impacting the viability or function of non-cancerous cells [120].